48.28
price up icon0.90%   0.43
after-market Handel nachbörslich: 48.29 0.010 +0.02%
loading
Schlusskurs vom Vortag:
$47.85
Offen:
$47.87
24-Stunden-Volumen:
20.78M
Relative Volume:
1.45
Marktkapitalisierung:
$98.25B
Einnahmen:
$47.64B
Nettoeinkommen (Verlust:
$5.42B
KGV:
18.08
EPS:
2.67
Netto-Cashflow:
$13.09B
1W Leistung:
+3.05%
1M Leistung:
-1.91%
6M Leistung:
-18.47%
1J Leistung:
+19.95%
1-Tages-Spanne:
Value
$47.30
$48.35
1-Wochen-Bereich:
Value
$46.10
$48.35
52-Wochen-Spanne:
Value
$39.35
$63.33

Bristol Myers Squibb Co Stock (BMY) Company Profile

Name
Firmenname
Bristol Myers Squibb Co
Name
Telefon
(609) 252-4621
Name
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Name
Mitarbeiter
34,100
Name
Twitter
@BMSNEWS
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
BMY's Discussions on Twitter

Vergleichen Sie BMY mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - General icon
BMY
Bristol Myers Squibb Co
48.28 95.34B 47.64B 5.42B 13.09B 2.67
Drug Manufacturers - General icon
LLY
Lilly Eli Co
737.67 640.72B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
155.21 367.98B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
ABBV
Abbvie Inc
186.11 323.71B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
115.76 222.69B 53.22B 12.86B 14.85B 6.39
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
71.50 299.26B 43.59B 15.04B 10.74B 3.3766

Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-22 Eingeleitet Cantor Fitzgerald Neutral
2025-04-22 Eingeleitet Piper Sandler Overweight
2024-12-16 Hochstufung Jefferies Hold → Buy
2024-12-10 Fortgesetzt BofA Securities Neutral
2024-11-15 Eingeleitet Wolfe Research Peer Perform
2024-11-13 Hochstufung Daiwa Securities Neutral → Outperform
2024-11-12 Hochstufung Leerink Partners Market Perform → Outperform
2024-10-25 Herabstufung Citigroup Buy → Neutral
2024-10-17 Eingeleitet Bernstein Mkt Perform
2024-07-29 Herabstufung Barclays Overweight → Equal Weight
2024-03-11 Herabstufung Societe Generale Buy → Hold
2024-02-06 Herabstufung Redburn Atlantic Buy → Neutral
2024-01-03 Herabstufung BofA Securities Buy → Neutral
2023-11-15 Herabstufung Cantor Fitzgerald Overweight → Neutral
2023-11-09 Eingeleitet Deutsche Bank Hold
2023-11-02 Herabstufung Daiwa Securities Outperform → Neutral
2023-10-27 Herabstufung BMO Capital Markets Outperform → Market Perform
2023-10-27 Hochstufung HSBC Securities Reduce → Hold
2023-10-27 Herabstufung William Blair Outperform → Mkt Perform
2023-10-20 Fortgesetzt UBS Neutral
2023-07-14 Eingeleitet HSBC Securities Reduce
2023-07-10 Eingeleitet SVB Securities Market Perform
2023-06-28 Eingeleitet Daiwa Securities Outperform
2023-03-06 Eingeleitet Jefferies Hold
2023-01-17 Eingeleitet Cantor Fitzgerald Overweight
2022-11-18 Eingeleitet Credit Suisse Neutral
2022-10-10 Herabstufung Guggenheim Buy → Neutral
2022-09-14 Herabstufung Berenberg Buy → Hold
2022-06-03 Herabstufung Raymond James Outperform → Mkt Perform
2022-04-06 Fortgesetzt Morgan Stanley Underweight
2021-12-17 Eingeleitet Goldman Buy
2021-12-09 Fortgesetzt Wells Fargo Equal Weight
2021-11-19 Eingeleitet BMO Capital Markets Outperform
2021-11-01 Herabstufung Argus Buy → Hold
2021-07-27 Fortgesetzt Truist Buy
2021-04-30 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-04-13 Hochstufung Truist Hold → Buy
2020-11-16 Hochstufung Societe Generale Hold → Buy
2020-11-10 Fortgesetzt Bernstein Mkt Perform
2020-11-06 Herabstufung Gabelli & Co Buy → Hold
2020-10-19 Hochstufung Guggenheim Neutral → Buy
2020-09-29 Eingeleitet Berenberg Buy
2020-07-28 Eingeleitet Raymond James Outperform
2020-04-02 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-03-23 Herabstufung Societe Generale Buy → Hold
2020-02-27 Eingeleitet Barclays Equal Weight
2020-01-06 Fortgesetzt Citigroup Buy
2019-12-13 Hochstufung Argus Hold → Buy
2019-11-22 Fortgesetzt Morgan Stanley Equal-Weight
2019-10-17 Fortgesetzt BofA/Merrill Buy
2019-08-14 Hochstufung Atlantic Equities Neutral → Overweight
2019-05-28 Eingeleitet Goldman Buy
2019-05-20 Herabstufung Argus Buy → Hold
2019-05-03 Hochstufung Barclays Equal Weight → Overweight
2019-05-03 Fortgesetzt JP Morgan Overweight
2019-01-15 Hochstufung Societe Generale Sell → Buy
2018-10-22 Herabstufung Citigroup Buy → Neutral
Alle ansehen

Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten

pulisher
May 30, 2025

BMO maintains Bristol-Myers Squibb stock at Market Perform By Investing.com - Investing.com India

May 30, 2025
pulisher
May 30, 2025

BMO maintains Bristol-Myers Squibb stock at Market Perform - Investing.com

May 30, 2025
pulisher
May 30, 2025

Another Bristol Myers exec goes to Acadia; David Southwell takes CEO job at ARCH-backed cancer biotech - Endpoints News

May 30, 2025
pulisher
May 29, 2025

Bispecific Antibody Drug Conjugates Clinical Trials Bispecific ADC Market Size Insight - GlobeNewswire Inc.

May 29, 2025
pulisher
May 29, 2025

BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications - TradingView

May 29, 2025
pulisher
May 29, 2025

EC approval for BMS’ subcutaneous Opdivo - The Pharma Letter

May 29, 2025
pulisher
May 29, 2025

Bristol Myers Loses 20.7% in 3 Months: Buy, Sell or Hold the Stock? - Yahoo Finance

May 29, 2025
pulisher
May 29, 2025

EC approves BMS’ nivolumab SC formulation for solid tumours - Yahoo Finance

May 29, 2025
pulisher
May 29, 2025

Fierce Biotech Layoff Tracker 2025: Keros cuts 70 jobs; iTeos winds down - Fierce Biotech

May 29, 2025
pulisher
May 29, 2025

Bristol Myers Squibb (BMY) Upgraded to Buy Amid Improved Dividen - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Bristol Myers Squibb bags European Commission nod for Subcutaneous formulation of Opdivo across multiple... - Medical Dialogues

May 29, 2025
pulisher
May 28, 2025

Bristol-Myers Squibb at Bernstein Conference: Strategic Growth and Innovation - Investing.com

May 28, 2025
pulisher
May 28, 2025

BMS says subcutaneous version of Opdivo gets EU nod - FirstWord Pharma

May 28, 2025
pulisher
May 28, 2025

Bristol Myers Squibb (BMY) Upgraded to Buy Amid Improved Dividend Prospects - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications - BioSpace

May 28, 2025
pulisher
May 28, 2025

Targeted Drug Delivery Research Business Analysis Report 2024-2030 with Focus on 30+ Key Players Such as AbbVie, Amgen, AstraZeneca, Becton Dickinson and Co, & Bristol-Myers Squibb - GlobeNewswire

May 28, 2025
pulisher
May 28, 2025

BMY Gains European Approval for New Opdivo Formulation | BMY Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance

May 28, 2025
pulisher
May 28, 2025

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications | HALO Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Bristol Myers: EU green light for Opdivo subcutaneous injection - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Bristol Myers (BMY) Gains European Approval for New Opdivo Formulation | BMY Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications | BMY Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - Yahoo Finance

May 28, 2025
pulisher
May 27, 2025

Bristol-Myers Squibb: This Undervalued Dog Needs An Option Collar (NYSE:BMY) - Seeking Alpha

May 27, 2025
pulisher
May 27, 2025

Bristol-Myers: Among The Cheapest Pharma Names, Now Yielding Above 5% (NYSE:BMY) - Seeking Alpha

May 27, 2025
pulisher
May 27, 2025

Bristol Myers Squibb’s SWOT analysis: stock faces challenges amid promising pipeline - Investing.com

May 27, 2025
pulisher
May 27, 2025

Deutsche Bank Accelerates Digital Transformation with IBM's Software Portfolio - The Globe and Mail

May 27, 2025
pulisher
May 26, 2025

Bristol Myers Squibb (BMY) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance

May 26, 2025
pulisher
May 23, 2025

Bristol-Myers Squibb (NYSE:BMY) Showcases Breakthrough Oncology Data at ASCO 2025 Meeting - simplywall.st

May 23, 2025
pulisher
May 22, 2025

Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline - Yahoo Finance

May 22, 2025
pulisher
May 22, 2025

Celgene Appeals Pennsylvania Tax After Bristol-Myers Acquisition - news.bloombergtax.com

May 22, 2025
pulisher
May 22, 2025

Areas of interest - Bristol Myers Squibb

May 22, 2025
pulisher
May 21, 2025

Bristol Myers, Novartis Take Drug Rebate Lawsuits to DC Circuit - Bloomberg Law News

May 21, 2025
pulisher
May 21, 2025

Tubulis achieves key milestone in BMS deal - The Pharma Letter

May 21, 2025
pulisher
May 20, 2025

Bristol Myers Squibb patents new BCL-6 degradation inducers - BioWorld MedTech

May 20, 2025
pulisher
May 20, 2025

Here's How You Can Earn $100 In Passive Income By Investing In Bristol-Myers Squibb Stock - Yahoo Finance

May 20, 2025
pulisher
May 19, 2025

Bristol Myers Squibb patents new USP1 inhibitors - BioWorld MedTech

May 19, 2025
pulisher
May 18, 2025

Bristol Myers Promises $40 Billion US Investment Over Five Years - MSN

May 18, 2025
pulisher
May 16, 2025

Bristol Myers Squibb (BMY) Gains EU Nod for Opdivo in Lung Cance - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Bristol Myers Squibb (BMY) Gains EU Nod for Opdivo in Lung Cancer Treatment - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Bristol Myers (BMY) Faces Market Movement Amid Medicare Part B & D Draft Guidance | BMY Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Bristol-Myers Curbs Investor $6.4 Billion Payout Suit on Appeal - Bloomberg Law News

May 16, 2025
pulisher
May 16, 2025

Jim Cramer On Bristol-Myers Squibb: “Waiting For It To Bottom” - Insider Monkey

May 16, 2025
pulisher
May 16, 2025

BMY Gains EU Approval for Expanded Use of Opdivo in Lung Cancer Treatment | BMY Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Reclaiming our time: Eightfold’s founder on the promise of agentic AI - HR Executive

May 16, 2025
pulisher
May 16, 2025

BMY Secures EC Approval for Opdivo Regimen in Lung Cancer Treatm - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Jim Cramer On Bristol-Myers Squibb: "Waiting For It To Bottom" - Yahoo Finance

May 16, 2025
pulisher
May 15, 2025

Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MSN

May 15, 2025
pulisher
May 15, 2025

Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know - MSN

May 15, 2025
pulisher
May 15, 2025

Bristol Myers Squibb (BMY) CEO Calls for Fair Global Drug Pricin - GuruFocus

May 15, 2025

Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
drug_manufacturers_general PFE
$23.49
price up icon 0.17%
$110.08
price down icon 0.93%
$288.18
price up icon 1.64%
drug_manufacturers_general GSK
$41.03
price up icon 2.58%
drug_manufacturers_general MRK
$76.84
price up icon 0.58%
drug_manufacturers_general NVO
$71.50
price up icon 2.94%
Kapitalisierung:     |  Volumen (24h):